News
On this last day of May «Bladder Cancer Awareness Month», the entire VitaDX team reiterates its support to patients by working every day to…
VitaDX was present at SANTEXPO 2022 to attend the Workshop "How to accelerate to Europe?"
VitaDX attended the first public conference dedicated to bladder cancer, organized by the University Hospital of Rennes and the Eugène Marquis…
Allan Rodriguez - CEO of VitaDX was interviewed by Destination Rennes to present the startup VitaDX and its in vitro diagnostic medical device…
Thanks to Ouest France for this very nice article.
VitaDX has been partnering for several years with LTSI (Signal and Image Processing…
Thomas Hugues welcomes Allan Rodriguez (VitaDX) and Camélia Radulescu (Foch hospital) to ÉCOSYSTÈME to talk about VitaDX's new diagnostic solution…
VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…
VitaDX is very proud to announce the CE marking of its first software solution dedicated to bladder cancer diagnosis: VisioCyt®.
This fundraising will allow VitaDX to finalize the development and ensure the commercial deployment of its first early bladder cancer detection…
On this last day of May «Bladder Cancer Awareness Month», the entire VitaDX team reiterates its support to patients by working every day to…
VitaDX was present at SANTEXPO 2022 to attend the Workshop "How to accelerate to Europe?"
VitaDX attended the first public conference dedicated to bladder cancer, organized by the University Hospital of Rennes and the Eugène Marquis…
Allan Rodriguez - CEO of VitaDX was interviewed by Destination Rennes to present the startup VitaDX and its in vitro diagnostic medical device…
Thanks to Ouest France for this very nice article.
VitaDX has been partnering for several years with LTSI (Signal and Image Processing…
Thomas Hugues welcomes Allan Rodriguez (VitaDX) and Camélia Radulescu (Foch hospital) to ÉCOSYSTÈME to talk about VitaDX's new diagnostic solution…
VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…
VitaDX is very proud to announce the CE marking of its first software solution dedicated to bladder cancer diagnosis: VisioCyt®.
This fundraising will allow VitaDX to finalize the development and ensure the commercial deployment of its first early bladder cancer detection…